Should an ACE inhibitor be stopped if signs of renal insufficiency appear?

Article Type
Changed
Tue, 05/03/2022 - 16:11
Display Headline
Should an ACE inhibitor be stopped if signs of renal insufficiency appear?
Article PDF
Author and Disclosure Information

Alejandro Morales, MD
Department of Medicine, Cleveland Clinic

Vincent W. Dennis, MD
Chairman, Department of Nephrology and Hypertension, Cleveland Clinic

Address: Vincent W. Dennis, MD, Department of Nephrology and Hypertension, A51,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Issue
Cleveland Clinic Journal of Medicine - 68(4)
Publications
Topics
Page Number
280, 282
Sections
Author and Disclosure Information

Alejandro Morales, MD
Department of Medicine, Cleveland Clinic

Vincent W. Dennis, MD
Chairman, Department of Nephrology and Hypertension, Cleveland Clinic

Address: Vincent W. Dennis, MD, Department of Nephrology and Hypertension, A51,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Author and Disclosure Information

Alejandro Morales, MD
Department of Medicine, Cleveland Clinic

Vincent W. Dennis, MD
Chairman, Department of Nephrology and Hypertension, Cleveland Clinic

Address: Vincent W. Dennis, MD, Department of Nephrology and Hypertension, A51,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 68(4)
Issue
Cleveland Clinic Journal of Medicine - 68(4)
Page Number
280, 282
Page Number
280, 282
Publications
Publications
Topics
Article Type
Display Headline
Should an ACE inhibitor be stopped if signs of renal insufficiency appear?
Display Headline
Should an ACE inhibitor be stopped if signs of renal insufficiency appear?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Should a patient with a brain tumor receive anticoagulation for a thromboembolic event?

Article Type
Changed
Wed, 12/26/2018 - 15:08
Display Headline
Should a patient with a brain tumor receive anticoagulation for a thromboembolic event?
Article PDF
Author and Disclosure Information

Alejandro Morales, MD
Department of General Internal Medicine, Cleveland Clinic

David J. Adelstein, MD
Department of Hematology and Medical Oncology, Cleveland Clinic

Address: David J. Adelstein, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail adelstd@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 68(1)
Publications
Topics
Page Number
13, 16
Sections
Author and Disclosure Information

Alejandro Morales, MD
Department of General Internal Medicine, Cleveland Clinic

David J. Adelstein, MD
Department of Hematology and Medical Oncology, Cleveland Clinic

Address: David J. Adelstein, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail adelstd@ccf.org

Author and Disclosure Information

Alejandro Morales, MD
Department of General Internal Medicine, Cleveland Clinic

David J. Adelstein, MD
Department of Hematology and Medical Oncology, Cleveland Clinic

Address: David J. Adelstein, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail adelstd@ccf.org

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 68(1)
Issue
Cleveland Clinic Journal of Medicine - 68(1)
Page Number
13, 16
Page Number
13, 16
Publications
Publications
Topics
Article Type
Display Headline
Should a patient with a brain tumor receive anticoagulation for a thromboembolic event?
Display Headline
Should a patient with a brain tumor receive anticoagulation for a thromboembolic event?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media